韩国生物制药巨头Celltrion今年营业利润首次突破1万亿韩元

Core Viewpoint - Celltrion expects its annual operating profit to exceed 1 trillion KRW (approximately 693 million USD) for the first time this year, driven by strong sales of high-end products [1][3]. Group 1: Financial Projections - The company forecasts that its operating profit will more than double from last year's 492 billion KRW to 1.16 trillion KRW by 2025, with sales projected to increase from 3.56 trillion KRW in 2024 to 4.11 trillion KRW [1][3]. - For the fourth quarter of this year, Celltrion anticipates an operating profit of 472.2 billion KRW and sales of 1.28 trillion KRW [1][3]. Group 2: Product Performance - The global sales growth of flagship biosimilars, including Remsima SC, Yuflyma, and Vegzelma, continues to boost annual profits [1][3]. - Biosimilars such as Remsima SC, Steqeyma, Yuflyma, and Vegzelma are expected to achieve double-digit sales growth globally, accounting for 60% of total sales [1][3]. Group 3: Strategic Focus - To maintain growth, the company will focus on promoting high-margin products while reducing the share of products with high raw material costs [2][4]. - Celltrion plans to launch contract manufacturing organization (CMO) products for Eli Lilly and introduce its own biosimilar products to the U.S. market through its New Jersey facility [2][4].